Real-world treatment patterns, biomarker testing, and clinical outcomes of metastatic non-small cell lung cancer patients in the immunotherapy era
Our real-world data support the benefit of single-agent PD-1 inhibitor monotherapy for patients with PD-L1 high expression or PD-1 inhibitor combination for all patients diagnosed with mNSCLC with no known EGFR/ALK/ROS1 aberrations, initiating 1L treatment.
Authors
- Lior Apter (ORCID: https://orcid.org/0009-0005-9557-4270)
- Sivan Gazit (ORCID: https://orcid.org/0000-0001-9875-3550)
- Ashwini Arunachalam (ORCID: https://orcid.org/0000-0003-4879-4770)
- Sarah Sharman Moser (ORCID: https://orcid.org/0000-0002-9745-2016)
- Nava Siegelmann‐Danieli (ORCID: https://orcid.org/0000-0001-7580-540X)
- Moshe Hoshen (ORCID: https://orcid.org/0000-0002-3107-5828)
- Gabriel Chodick (ORCID: https://orcid.org/0000-0002-5189-8995)
Institutions
- Ben-Gurion University of the Negev (IL)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Tel Aviv University (IL)
- Maccabi Institute for Health Services Research (IL)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-10-25
- DOI
- https://doi.org/10.3389/fonc.2024.1442909
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.28